Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders. / Mansur, Rodrigo B; Zugman, Andre; Ahmed, Juhie; Cha, Danielle S; Subramaniapillai, Mehala; Lee, Yena; Lovshin, Julie; Lee, Jung G; Lee, Jae-Hon; Drobinin, Vladislav; Newport, Jason; Brietzke, Elisa; Reininghaus, Eva Z; Sim, Kang; Vinberg, Maj; Rasgon, Natalie; Hajek, Tomas; McIntyre, Roger S.
In: European Neuropsychopharmacology, Vol. 27, No. 11, 2017, p. 1153-1162.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders
AU - Mansur, Rodrigo B
AU - Zugman, Andre
AU - Ahmed, Juhie
AU - Cha, Danielle S
AU - Subramaniapillai, Mehala
AU - Lee, Yena
AU - Lovshin, Julie
AU - Lee, Jung G
AU - Lee, Jae-Hon
AU - Drobinin, Vladislav
AU - Newport, Jason
AU - Brietzke, Elisa
AU - Reininghaus, Eva Z
AU - Sim, Kang
AU - Vinberg, Maj
AU - Rasgon, Natalie
AU - Hajek, Tomas
AU - McIntyre, Roger S
N1 - Copyright © 2017 Elsevier B.V. and ECNP. All rights reserved.
PY - 2017
Y1 - 2017
N2 - Cognitive deficits are a core feature across psychiatric disorders. Emerging evidence indicates that metabolic pathways are highly relevant for the substrates and phenomenology of the cognitive domain. Herein, we aimed to determine the effects of liraglutide, a GLP-1R agonist, on brain structural/volumetric parameters in adults with a mood disorder. This is the secondary analysis of a 4-week, pilot, proof-of-concept, open-label study. Participants (N=19) exhibiting impairments in executive function with either major depressive disorder (MDD) or bipolar disorder (BD) were recruited. Liraglutide 1.8mg/day was added as an adjunct to existing pharmacotherapy. Structural magnetic resonance imaging (MRI) scanning was obtained at baseline and endpoint. Results showed that at endpoint there was significant weight loss (mean: 3.15%; p<0.001). Changes in frontal and striatal volumes were significantly correlated with changes in body mass index (BMI), indicating the weight loss was associated with volume increase in most regions (e.g. r=-0.561, p=0.042 in the left superior frontal area). After adjusting for intracranial volume, age, gender, and BMI, we observed significant changes from baseline to endpoint in multiple regions (e.g. RR: 1.011, p=0.049 in the left rostral middle frontal area). Changes in regional volumes were associated with improvement in executive function (e.g. r=0.698, p=0.003 for the right superior frontal area). Adjunctive liraglutide results in clinically significant weight loss, with corresponding improvement in cognitive function; changes in cognitive function were partially moderated by changes in brain morphometry, underscoring the interrelationship between weight and brain structure/function.
AB - Cognitive deficits are a core feature across psychiatric disorders. Emerging evidence indicates that metabolic pathways are highly relevant for the substrates and phenomenology of the cognitive domain. Herein, we aimed to determine the effects of liraglutide, a GLP-1R agonist, on brain structural/volumetric parameters in adults with a mood disorder. This is the secondary analysis of a 4-week, pilot, proof-of-concept, open-label study. Participants (N=19) exhibiting impairments in executive function with either major depressive disorder (MDD) or bipolar disorder (BD) were recruited. Liraglutide 1.8mg/day was added as an adjunct to existing pharmacotherapy. Structural magnetic resonance imaging (MRI) scanning was obtained at baseline and endpoint. Results showed that at endpoint there was significant weight loss (mean: 3.15%; p<0.001). Changes in frontal and striatal volumes were significantly correlated with changes in body mass index (BMI), indicating the weight loss was associated with volume increase in most regions (e.g. r=-0.561, p=0.042 in the left superior frontal area). After adjusting for intracranial volume, age, gender, and BMI, we observed significant changes from baseline to endpoint in multiple regions (e.g. RR: 1.011, p=0.049 in the left rostral middle frontal area). Changes in regional volumes were associated with improvement in executive function (e.g. r=0.698, p=0.003 for the right superior frontal area). Adjunctive liraglutide results in clinically significant weight loss, with corresponding improvement in cognitive function; changes in cognitive function were partially moderated by changes in brain morphometry, underscoring the interrelationship between weight and brain structure/function.
U2 - 10.1016/j.euroneuro.2017.08.433
DO - 10.1016/j.euroneuro.2017.08.433
M3 - Journal article
C2 - 28867303
VL - 27
SP - 1153
EP - 1162
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
SN - 0924-977X
IS - 11
ER -
ID: 194917548